KRAS has been a constant hot topic for conversation for the past two years. An area where giants like Mirati and Amgen haven’t stopped to focus and perform, and now things have started to get interesting on the development side. We, Mellalta Meets has gathered important developmental insights on KRAS market activities.
Metastatic colorectal cancer (mCRC) + KRAS Inhibitors
Patients with metastatic colorectal cancer (mCRC) have very poor overall survival despite the use of irinotecan or oxaliplatin-based chemotherapy combined with anti-EGFR (epidermal growth factor receptor) drugs, in particular those with KRAS oncogene mutation.
mCRC patients with KRAS mutations have limited targeted therapeutic options. And with countries like the United States and the United Kingdom where mortality rates are more than normal, it becomes a serious problem.
There have been over 200 FDA approved products for adult cancers in the past 20 years, yet we have not seen any therapy with 100% accuracy.
However, over the past two years, pharmaceutical companies have realized the importance and therefore many giants have taken a step forward. With Mirati and Amgen, a consolidated nucleus in this field and at the forefront, many other companies have also started showing their interest.
On May 13, Cardiff Oncology entered into an agreement with PoC Capital to fund Onvansertib’s Phase 2 clinical trial in KRAS mutant metastatic colorectal cancer (mCRC).
According to recent rumors and news, we, Mellalta Meets have discovered that Cardiff Oncology has entered into a stock purchase agreement with its board of directors and its CEO, under which it has sold 594,615 shares of common stock for gross proceeds of $ 810,000.
On the other hand, Fortress Biotech has licensed a treatment for KRAS-driven tumors from Columbia University. Adhering to its plan, Fortress has set up another biotech, Oncogenuity, to advance the pre-clinical asset and work to generate more oligonucleotides from the underlying platform.
Given the platform’s ability to target any mutation, Oncogenuity will continue to evaluate other mutations simultaneously. The company anticipates additional data publications in the coming 12 months.
And with several other companies that are already studying this field, such as Elicio Therapeutics in collaboration with the National Cancer Institute, we can see something vital that adapts to the time.
KRAS inhibitors-Market opportunity, Epidemiology & Market Forecast, Pipeline and Competitive Analysis, 2020-2030